Health In Tech, Inc. (NASDAQ: HIT) is drawing mixed signals from Wall Street after Maxim Group issued updated earnings estimates for the insurance technology company on Friday, August 14th. Analyst A. Klee projects a per-share loss of $0.04 for the third quarter of 2026, part of a broader forecast that stretches through fiscal year 2027. The estimates land at a moment when investors are trying to reconcile a "Buy" rating and a $3.00 price target with a stock that has picked up a "sell" call elsewhere on the Street.
Maxim Group's full forecast paints a picture of a company still working toward consistent profitability. The firm expects a $0.03 per-share loss in the fourth quarter of 2026, bringing the full fiscal year 2026 loss to $0.10 per share. Looking further out, Maxim projects a modest $0.01 per-share profit in the first quarter of 2027, followed by a $0.01 loss in the second quarter, breakeven in the third quarter, and another $0.02 loss in the fourth quarter - netting a $0.02 per-share loss for fiscal year 2027 overall. That trajectory suggests a company narrowing its losses over time rather than one already generating steady earnings, which is typical for smaller technology firms still scaling their platforms. cannabis pos software new mexico
A Divided Analyst Field
Not every research shop shares Maxim's optimism. Wall Street Zen downgraded Health In Tech from "hold" to "sell" back on Saturday, April 25th, a notable shift given the stock's otherwise favorable coverage. Craig Hallum took the opposite stance, initiating coverage on Monday, April 20th with a "buy" rating and a $4.00 price target - the most bullish figure among the analysts tracked. Weiss Ratings, meanwhile, restated a "sell (d)" rating on Tuesday, June 30th, reinforcing the skepticism already present in Wall Street Zen's call.
Taken together, one analyst rates the stock Strong Buy, one rates it Buy, and one rates it Sell. That spread is worth sitting with for a moment. It's not a case of near-unanimous conviction in either direction; it's a genuine disagreement about how to value a company whose earnings picture, per Maxim's own numbers, remains negative for the next several quarters.
What The Consensus Actually Says
According to data compiled by MarketBeat.com, Health In Tech currently holds a consensus rating of "Moderate Buy" with an average price target of $3.50. That consensus sits comfortably between the more conservative and more aggressive price targets circulating among individual analysts, which is often what happens when a stock has real disagreement baked into its coverage rather than a uniform view.
For investors watching HIT, the practical takeaway is straightforward: near-term profitability isn't the story here, at least not by Maxim's estimates. The story is whether the company's trajectory toward smaller losses - and eventual breakeven quarters, as projected for early 2027 - plays out as modeled, and whether that's enough to justify price targets that range meaningfully across the analyst community. Investors weighing a position would do well to look past the rating labels themselves and examine the underlying earnings assumptions driving them, since a "Buy" and a "Sell" can sometimes rest on very different views of the same numbers.
